Capital Markets & Financing
China’s Shein denies U.S. IPO rumors
Chinese fast fashion giant Shein on Friday denied a Reuters report that said it has confidentially filed for an initial public offering in the U.S.
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that it has successfully completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of NT$75 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,312.5 million (or US$42.3 million at FX=31).
Adicon Holdings Ltd., a Chinese diagnostic lab, announced it will raise $52.3 million by issuing 33.2 million shares via a global offering, with shares priced at $1.57 each. Read more here.
Chinese diagnostic lab company Adicon Holdings Ltd. on Monday said it will raise HK$408.9 Million ($52.29 million) via a global offering through the issuing of 33.2 million shares.
Syngenta Wins Exchange Approval for $9.1 Billion Shanghai IPO
Syngenta Group won approval from the Shanghai stock exchange for its 65 billion yuan ($9.1 billion) initial public offering, moving the world’s biggest potential listing this year a step closer to completion.
China imposes limits on Russian banks
The recent visit of US Secretary of State Anthony Blinken to China and the Bank of China's subsequent decision to restrict Russian bank clients’ transactions involving banks located in the EU, the United States, Switzerland and the UK, could be a coincidence.
Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease
June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment.
Hong Kong’s VMS Group eyes up to $400m for flagship PE fund
Hong Kong alternative asset management firm VMS Group is targeting $300 million for its flagship private equity fund, with a hard cap of $400 million.
Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited
SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is in advanced discussion with its Company's Chairman and Chief Executive Officer, Mr. Hong Zhida, to acquire Mr Hong's partial stake in Shanghai Bao Pharmaceutical Company Limited.
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases
BOSTON and SHANGHAI, June 11, 2023 /PRNewswire/ -- Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, today announced a CNY 180 million (about $25 million) Series B financing.
